Biomarkers can be used in a variety of ways for the management of patients with neuroendocrine tumors (NETs).

Differences exist in the clinical behavior of neuroendocrine tumors (NETs) based on the site of origin and histologic characteristics, Matthew H. Kulke, MD, points out.

In the first installment of the series, the moderator, Matthew H. Kulke, MD, provides an overview and brief description of neuroendocrine tumors (NETs) and introduces the panel.

Marvin A. Konstam, MD, director of Tufts Medical Center’s cardiovascular unit, in Boston, MA, discusses different investigational indications for vasopressin receptor antagonists in heart failure patients, including those without hyponatremia.

Marvin A. Konstam, MD, of Tufts Medical Center’s cardiovascular unit, in Boston, MA, pits the effectiveness of vasopressin receptor antagonists against the standard fluid restriction approach to treating hyponatremia.

Marvin A. Konstam, MD, director of Tufts Medical Center’s cardiovascular unit, in Boston, MA, discusses circumstantial evidence that hyponatremia may have an adverse effect in heart failure patients.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the factors cardiologists consider in selecting specific beta blockers for heart failure patients.

Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses the SHIFT study’s value for cardiologists over various recent heart failure trials.